Next Article in Journal
How to Overcome a Snail? Identification of Putative Neurotoxins of Snail-Feeding Firefly Larvae (Coleoptera: Lampyridae, Lampyris noctiluca)
Previous Article in Journal
Pierisin, Cytotoxic and Apoptosis-Inducing DNA ADP-Ribosylating Protein in Cabbage Butterfly
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a “High Value” Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections

Department of Health Sciences at Extension, University of California Los Angeles, 1145 Gayley Ave., Los Angeles, CA 90024, USA
Toxins 2024, 16(6), 271; https://doi.org/10.3390/toxins16060271
Submission received: 3 May 2024 / Revised: 9 June 2024 / Accepted: 12 June 2024 / Published: 14 June 2024

Abstract

:
Extensively drug-resistant Pseudomonas aeruginosa infections are emerging as a significant threat associated with adverse patient outcomes. Due to this organism’s inherent properties of developing antibiotic resistance, we sought to investigate alternative strategies such as identifying “high value” antigens for immunotherapy-based purposes. Through extensive database mining, we discovered that numerous Gram-negative bacterial (GNB) genomes, many of which are known multidrug-resistant (MDR) pathogens, including P. aeruginosa, horizontally acquired the evolutionarily conserved gene encoding Zonula occludens toxin (Zot) with a substantial degree of homology. The toxin’s genomic footprint among so many different GNB stresses its evolutionary importance. By employing in silico techniques such as proteomic-based phylogenetic tracing, in conjunction with comparative structural modeling, we discovered a highly conserved intermembrane associated stretch of 70 amino acids shared among all the GNB strains analyzed. The characterization of our newly identified antigen reveals it to be a “high value” vaccine candidate specific for P. aeruginosa. This newly identified antigen harbors multiple non-overlapping B- and T-cell epitopes exhibiting very high binding affinities and can adopt identical tertiary structures among the least genetically homologous P. aeruginosa strains. Taken together, using proteomic-driven reverse vaccinology techniques, we identified multiple “high value” vaccine candidates capable of eliciting a polarized immune response against all the P. aeruginosa genetic variants tested.
Key Contribution: Combinatorial in silico techniques reveal that the evolutionary conserved gene encoding Zonula occludens toxin has horizontally passed through numerous GNB genomes, including many known MDR-GNB pathogens. The characterization of the toxin reveals the presence of a highly conserved intermembrane associated stretch of 70 amino acids shared among all the genetic variants tested and serves as a “high value” vaccine candidate specific for treating P. aeruginosa infections.

1. Introduction

Epithelial tissues comprise tightly woven sheets of avascular cells distributed throughout the body, covering both the internal and external surfaces, lining the deep layers of organs, and performing a variety of physiological functions [1,2,3,4,5,6,7,8,9]. Tight junctions (TJs) are the subcellular structures essential for maintaining a continuously interconnected epithelial monolayer [10,11,12,13]. TJs comprise a multiplex arrangement of both cytosolic and integral membrane proteins that physically interconnect adjacent epithelial cells, establishing an impenetrable seal [12,13,14,15,16,17,18,19,20,21]. Although epithelial tissues serve as strong protective barriers that prevent infectious agents from disseminating, numerous Gram-negative bacterial (GNB) pathogens have horizontally acquired an evolutionary conserved virulence factor; Zonula occludens toxin (Zot), capable of commandeering host-cell TJ multiplexes and mediating the paracellular transport into the deeper layers of host tissues [22,23,24,25,26]. The toxins highly conserved horizontal passage among multitudes of GNB, with a very high degree of homology, strongly emphasizing its vital importance in the evolution of GNB pathogenesis; specifically for dissemination purposes.
Zonula occludens toxin is encoded by a wide variety of GNB pathogens and displays properties that enhance the microbial permeation between epithelial monolayers. Zot is an outer membrane protein originally identified in the toxigenic GNB pathogen, Vibrio cholerae [22,24,26]. The toxin, along with a variety of other virulence factors, is predominantly part of a pathogenicity island encoded by the filamentous phage, CTXΦ, which is responsible for the horizontal transfer of several virulence genes to V. cholera [25,27]. Zot displays host protein mimicry functions that regulate the microbial passage between physically linked epithelial cells. Based on the virulence properties exhibited by Zot, its main role in host–pathogen interaction is associated with inducing signaling cascades that control epithelial cell tight junctional complexes and mediate the paracellular passage into the deeper layers of tissue [22,23,26,28,29,30]. Affinity-purified anti-Zot antibodies show that the subcellular localization of V. cholerae-derived Zot is on the outer membrane and has a molecular mass of ~45 kDa. Additionally, a second immunoreactive protein analogous to the ~33 kDa amino terminus of Zot has also been identified to be membrane bound. The ~33 kDa transmembrane fragment is further processed at a cleavage site located at amino acid residue 287 [26]. The final biologically active toxigenic fragment (of ~12 kDa) localized to the carboxyl terminus is released into the host intestinal milieu, where it binds specific cell surface receptors present on the mature cells of small intestinal villi and initiates a signal transduction cascade to commandeer the dissociation of tight junctions [22]. In addition to being encoded by V. cholerae and many more GNB, genome annotation studies reveal the presence of Zot-encoding genes in the genomes of numerous Pseudomonas aeruginosa genetic variants. This ability to control paracellular transport by deploying Zot is what enables the highly invasive progression of P. aeruginosa into the deeper layers of tissue, and the subsequent dissemination to the distal anatomical regions.
P. aeruginosa produces a multitude of intrinsic and acquired virulence factors that enable it to adapt to its host. These virulence factors are deployed at different stages of disease, depending on the variations in the host’s environmental factors and immune defenses [31]. These virulence factors are grouped based on whether they are cytosolic effectors, membrane bound, or secreted into the extracellular milieu [32,33,34,35,36]. Cytosolic effector proteins are injected into host cells to rapidly commandeer host functions and actively regulate shifts in metabolism, physiochemistry, and morphology [37,38]. Membrane-bound factors mediate the physical host/pathogen interaction and biofilm formation [39,40,41,42,43]. Secreted toxins shape the overall pathogenic capacity of P. aeruginosa, by enabling it to carry out a multitude of functions that exploit its host. These secreted toxins exert their affects in a variety of ways such as molecular mimicry, directly damaging host cells, enzymatic hydrolysis, providing dissemination capabilities, diverting or interfering with the host’s inflammatory responses, and enhanced quorum sensing capabilities [31,36,44,45,46,47,48,49]. Traditionally, secreted virulence factors are commonly used as vaccine antigens for immunization strategies and display a minimal likelihood of the emergence of therapeutic resistance [36,50,51]. Accordingly, Zot’s highly pervasive characteristic and extensive homology shared amongst numerous GNB pathogens further stresses its importance in P. aeruginosa pathogenesis and serves as a “high value” vaccine candidate for the development of multi-strain immunotherapy-based treatment modalities.
It is estimated that bacterial infections account for approximately 7.7 million worldwide deaths annually [52,53]. Surgical sites represent the leading cause of infections, followed by urinary tract, bacteremia, pneumonia and other forms of bacterial diseases [52,53]. P. aeruginosa exhibits remarkable clinical importance as it accounts for 7% amongst all nosocomial infections and is the cause of 23% of all ICU-acquired infections [54]. P. aeruginosa is a ubiquitous, non-spore forming, aerobic, Gram-negative bacilli that primarily favors wet and humid niches [55]. It is an extensive MDR pathogen that causes a multitude of infections in both immunocompetent and immunocompromised hosts [56,57]. The pathogen can originate from either exogenous or endogenous sources, such as an individual’s microflora, central lines, catheters, ventilators, healthcare workers and other non-mechanical associated infection systems like enteric and bloodstream, which are the primary sources [57]. Second to the Gram-positive pathogen, Staphylococcus aureus, P. aeruginosa is the leading GNB pathogen identified among healthcare-associated pneumonia cases and accounts for ~26% of global infections [53]. The mortality due to ventilator-associated pneumonia secondary to P. aeruginosa is estimated to be as high as 32–42.8% [54]. P. aeruginosa is frequently associated with catheter infections, bacteremia, surgical site, burn wound and urinary tract infections (UTI) and is the predominant cause of morbidity and mortality in cystic fibrosis patients [54,58]. In its extreme form, uncontrolled P. aeruginosa infections are fatal [54]. These infections are generally managed with antibiotics; however, the rapid rise in MDR nosocomial strains has made them very difficult to treat [59]. Accordingly, we have sought to identify antibiotic independent strategies for preventing/treating MDR P. aeruginosa-associated disease.
Herein, we report a reverse vaccinology strategy utilizing proteomic-based phylogenetic tracing approaches to reconstruct the evolutionary history of Zot and assess its relatedness among a variety of different MDR-GNB pathogens [60,61,62,63,64]; these include, but are not limited to, P. aeruginosa, Neisseria gonorrhoeae, Neisseria meningitidis, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Salmonella enterica, Yersinia pestis and V. cholerae. First, we performed an extensive database mining analysis and identified the evolutionary conserved virulence factor, Zot, encoded by numerous MDR-GNB, including several P. aeruginosa genetic variants. Using P. aeruginosa as our model organism, we performed both nucleic acid and protein-based phylogenetics, in conjunction with utilizing sequence alignment and structural modeling to identify long stretches of evolutionary conserved amino acid sequences shared among all different P. aeruginosa strains queried. Accordingly, we identified a highly conserved loci, in the native Zot protein, comprised of an intermembrane-associated stretch of 70 amino acids with very high antigenic potential. Upon characterizing our newly discovered antigen, we noticed its properties to be classified as a “high value” vaccine candidate for the treatment of a multitude of MDR-GNB pathogens, including P. aeruginosa infections.

2. Results

Proteomic mining identifies evolutionarily conserved Zonula occludens toxin homologs distributed throughout the numerous clinically relevant GNB pathogens. To trace the phylogenetic relationship of Zot among different GNB pathogens, the multiple protein sequence alignment algorithm, MUSCLE, was used [65]. First, we performed an extensive UniProt search with Zonula occludens toxin as the query (accessed 26 February 2024). Of the 284 predicted individual protein entities identified, the closest full-length matches (≥345 amino acids) to the V. cholerae Zot protein sequence were chosen. A total of 150 different protein entities and 35 species-specific bacteriophages were identified. All the identified protein entities were distributed among eight different clinically relevant MDR-GNB pathogens: P. aeruginosa, V. cholerae, N. gonorrhoeae, N. meningitidis, A. baumannii, K. pneumoniae, E. coli, S. enterica and Y. pestis (Figure 1A). It should be noted that the database mining results did not reveal the presence of Zot-like proteins associated with any Gram-positive bacteria, suggesting that the evolutionary path of Zot is only restricted to GNB pathogens. The different composition of Gram-positive vs. Gram-negative bacterial cell walls may be a contributing factor responsible for the restricted evolution of the toxin to the outer membrane of GNB pathogens.
Zot protein-mediated phylogenetic comparisons of the eight different pathogens revealed that they are all distributed into four different clades and two outgroup lineage (Figure 1B). Clade one is subdivided into two nested clades including Neisseria spp. and A. baumannii. Additionally, the Neisseria spp. nested clade also shares an ancestry with four different P. aeruginosa strains. Clade two shows a shared ancestry between the majority of different S. enterica strains and three of six identified E. coli strains. Moreover, one K. pneumoniae and one P. aeruginosa strains were also included in clade two. Interestingly, the phylogram shows that S. enterica-encoded Zot shares a high degree of homology with human-associated Zonula occludens (-1, -2, -3) and occludin proteins, which are also included in clade two. Clade three exhibits a shared ancestry between most P. aeruginosa strains and all identified V. cholerae stains. Clade four is the most diverse of all and includes a mixture of five different GNB pathogens. Specific strains of P. aeruginosa, S. enterica, E. coli, K. pneumoniae and Y. pestis were all found to be present in clade four. In contrast, the three other clades were more species-defined and not as diverse. In addition to the presence of the four different clades, there appears to be two outgroup lineages designated the number five on the phylogram (Figure 1B). These outgroup lineages only comprise a few P. aeruginosa strains and do not display any common ancestry with any of the four clades. To assess the contribution of bacteriophages to the horizontal transfer of Zot, several phages were identified and included in our phylogenetic studies. The results indicate the presence of multiple species-specific bacteriophages distributed throughout each clade and cluster (Figure 1A,B).
A comparative analysis of the phylogenetic relationship among different bacteriophages expressing Zot showed their evolutionary passage into 7 clads. For example, clad one comprises phages belonging to V. cholerae and all of P. aeruginosa. Clad two is restricted to only V. cholerae phages. Clad three contains E. coli, V. cholerae and Y. pestis phages. Clad four is only restricted to S. enterica phages. Clade five only has A. baumannii phages. Clad 6 has a mixture of N. gonorrhoeae and N. meningitidis phages. Lastly, clad seven is comprised mainly of A. baumannii phages and a single P. aeruginosa phage (Figure 1C).
The multiple sequence alignments of Zot reveal a high degree of nucleotide and amino acid sequence homology among many different P. aeruginosa genetic variants. Using our nucleic acid-based alignment data, we constructed a phylogenetic tree and traced the nucleotide distribution of the homo- and heterogeneous sequences of the Zot gene, among different P. aeruginosa strains. Our phylogenetic data show that 32 different strains are distributed among 21 unique clusters and 14 different clads. Of the 14 clades, 8 are nested and represent a total of 26 different strains. Furthermore, the phylogram revealed the presence of two out-group lineages comprising three different P. aeruginosa strains that do not show a close ancestry to any of the other 29 genetic variants (Figure 2A). Quantitative assessment of the nucleic acid sequence homology, between the 21 unique P. aeruginosa clusters, revealed a range between 81% and 100% sequence identity, with a query coverage of 58% to 100% (Figure 2B). A graphical representation of the nucleotide sequence homology among the different strains reveals very short, dispersed stretches of non-homologous regions (marked in red) located in the mid and N-terminal regions of the Zot gene, possibly displaying strain- and/or niche-specific nucleotide sequences (Figure 2C).
Our proteomic-based phylogenetic studies show that 32 different strains were distributed among 23 unique clusters and 11 different clads. Of the 11 clades, 6 are nested and represent a total of 26 different genetic variants. Additionally, the phylogram also revealed the presence of 2 outgroup lineages comprising 6 different P. aeruginosa strains that do not show any close ancestry to the other 27 variants (Figure 2D). The quantitative assessment of amino acid sequence homology showed a range between 22.58% and 100% identity, with query coverage of 28% to 100% (Figure 2E). Orange circles represent each clad.
The proteomic-based sequence alignments of Zot identify the presence of a long stretch of 70, evolutionary conserved, amino acids shared among numerous P. aeruginosa genetic variants. Multiple sequence alignment tools are key components in predicting the protein structure and function properties and are ideal for identifying evolutionarily conserved stretches of amino acid sequences that can serve as “high value” vaccine candidates, capable of targeting the maximum number of P. aeruginosa strains. A total of 29 different P. aeruginosa genetic variants were analyzed in this study. Accordingly, our proteomic data of Zot reveals the presence of several stretches of highly conserved amino acid sequences dispersed though different regions of the toxin (red color). As can be seen in the graphical representation, there appears to be a very long stretch of highly conserved amino acid sequences positioned near the mid-left section of the Zot protein (Figure 3A). To further investigate this highly conserved region, we specifically chose the linear stretch of amino acids located between arginine 153 and leucine 223. The alignment of this newly identified 70 amino acid multi-strain antigen shows that all the strains are divided into eight subgroups, based on the sequence homology (Figure 3B). The number of strains per group is as follows: (1) 14 strains, (2) 6 strains, (3) 2 strains, (4) 2 strains, (5) 2 strains, (6) 2 strains, (7) 1 strain and (8) 1 strain.
It is well established that transmembrane proteins serve a significant role in maintaining proper cell functions such as mediating signal transduction, transmembrane transport, cell communication and most notably virulence [66]. Accordingly, transmembrane proteins are considered ideal vaccine candidates due to the exposure of highly immunogenic epitopes present on the outer membrane [67,68]. Most alleles encoding major histocompatibility complex I and II (MHC-I, -II) are generally hydrophobic in character, and the peptides derived from transmembrane proteins are predicted to be present more often. This high MHC binding capacity of transmembrane peptide domains is based on their displayed hydrophobic nature [67,68]. Furthermore, transmembrane proteins tend to be evolutionarily conserved among many different strains and across many different Gram-negative bacterial species, as is the case with our newly identified “high value” antigen. While most research is focused on identifying epitopes with specific antigenicity, we sought to determine in which domain our newly identified antigen is located. Such assessment will shed light on the immunogenic potential of our new vaccine candidate.
Published reports reveal that signal peptides and transmembrane domains are characterized by exceptionally high epitope densities [67,68]. Accordingly, our annotation studies comparing V. cholerae and the P. aeruginosa Zot protein sequence reveal that our newly identified stretch of 70 amino acids is associated with the outer transmembrane of both species (Figure 4). A protein sequence comparison reveals a high degree of homology in the N-terminal domain of Zot. Data show that V. cholerae- and P. aeruginosa-encoded Zot proteins share 39% sequence homology and 54% positive sequence identities. Additionally, our analysis reveals the presence of a P-loop domain located within our target antigen (Figure 4). The presence of a conserved walker A motif, within our “high value” antigen, strongly suggests a functional role in transmembrane ATP binding and hydrolysis. Interestingly, our results also show that the cleavage site of the V. cholerae C-terminal domain is not present in the P. aeruginosa Zot protein, strongly indicating an alternative proteolytic processing for P aeruginosa-encoded Zot due to niche-associated conditions (Figure 4). Taken together, our results reveal that our “high value” vaccine candidate is localized to the transmembrane and characterized to exhibit high immunogenic potential. In the following section, the high epitope density of our antigen will be assessed using bioinformatic techniques and corroborated by the high percentage of identified epitopes in the IEDB (immune epitope database).
The generation of a protective immune response is highly dependent on the immunogenicity of an antigen. Immunogenicity refers to the degree of an antigen eliciting an immune response, which ranges from short-term immunity to long-term protection against a pathogen. Published reports reveal that the full-length, recombinant V. cholerae Zot protein is highly immunogenic. The intranasal immunization of mice with native recombinant Zot induces a very robust protective immune response, with approximately a 40-fold increase in serum immunoglobulin G (IgG) titers. These data also show that recombinant Zot stimulates high IgA titers in serum, as well as vaginal and intestinal secretions [69,70].
To assess the immunogenic potential of our newly identified antigen, we performed a series of computational studies to determine the binding affinity of our intermembrane-associated stretch of 70 amino acids in the context of both MHC classes and a B cell receptor/antibody. By utilizing the Immune Epitope Database Analysis (IEDA) algorithm, we identified the presence of several, non-overlapping stretches of amino acids with very high immunogenic potential. In the context of MHC-I, we identified four distinct epitopes with very high binding affinity, ranging from 90% to 97% (Figure 5A). Additionally, our results show that these four epitopes do not overlap and are widely distributed throughout the 70-amino acid antigen. The analysis of MHC-II specific epitopes revealed the presence of three different non-overlapping regions of 15 amino acids with binding affinities between 68% and 80% (Figure 5B). Lastly, the analysis of our antigen shows two distinct regions with a high potential for serving as B cell receptor/antibody binding peptides. Advantageously, these two newly identified B cell peptides also span different regions of the same 70-amino acid antigen (Figure 5C). Taken together, our data further confirm the immunogenic potential of our newly identified “high value” antigen specific for multiple P. aeruginosa genetic variants.
An antigen’s conformational integrity is of crucial importance for high receptor/antibody binding affinity and proper intracellular trafficking from the initial uptake to antigen processing and cell surface display by antigen presenting cells (APC). The inherent structural characteristics have a great impact on antigen immunogenicity and the polarization of a robust immune response. Structural stability enhances the vaccine potency by increasing the rate of antigen proteolysis, antigen presentation and the induction of both humeral and cell-mediated responses. To assess the structural properties of our newly identified “high value” antigen, we used the Swiss-Model algorithm. First, we localized the conserved linear intermembrane-associated stretch of 70 amino acids to be situated between arginine 153 and leucine 223 of the native Zot protein (genetic variant: A0A1C7BT03). In the native form, our structural data show that amino acids between arginine 153 and arginine 197 adopt three antiparallel β strands, within a β-pleated sheet, and amino acids ranging from isoleucine 197 to serine 208 display a short helical configuration (Figure 6A). A comparative analysis of the complete native Zot protein versus our 70-amino acid antigen reveals a very high degree of structural homology. The newly identified intermembrane-associated antigen adopts the same antiparallel β-pleated sheet pattern and small helical conformation as can be observed in the native form. Furthermore, the structural comparison of the evolutionary conserved stretch of 70 amino acids among two of the least homologous strains (A0A1C7BT03 vs. O86426) show them both adopting the same identical conformation, at different amino acid positions relative to the native protein (Figure 6B). The quantitative assessment of the protein sequence homology between the two genetic variants reveals a percentage identity of 18% (Figure 6C). The adoption of identical conformations with such a high degree of sequence heterogeneity between the two strains continues to stress the importance of our newly identified 70-amino acid “high value” therapeutic antigen.

3. Discussion

Decade-long varying selective pressures have led to the vigorous global rise in a plethora of multidrug-resistant (MDR) Gram-negative bacteria (GNB). The lack of innovation directed at identifying new classes of antimicrobials is threatening the efficacy of the limited number of antibiotics currently used in clinical practice. International antimicrobial drug-development pipelines have become stagnant and have not kept on par with the inevitable reemergence of MDR pathogens [71]. This is beginning to undermine the worldwide healthcare systems, as more pathogens become extensively drug resistant while less novel antimicrobials are making it to market [72]. The intrinsic evolution of drug resistance against conventional antibiotics drives their limited lifespan and prompts the need to develop treatment modalities that mitigate the establishment of MDR [73]. At the current pace, soon, interventions such as basic surgical procedures and immunosuppressing chemotherapies would be accompanied by the increased risk of a life-threatening infection.
The genera Pseudomonas are a type of ubiquitous Gram-negative bacteria that commonly occupy soil and aquatic niches. Of the many different types of Pseudomonas, the species that is the leading cause of nosocomial GNB infections in humans is called Pseudomonas aeruginosa, a well-known hospital-acquired superbug that readily causes bacteremia, pneumonia, wound, burn and surgical site infections in both immunocompetent and immunocompromised individuals. P. aeruginosa infections are the leading cause of morbidity and mortality in patients afflicted with cystic fibrosis. P. aeruginosa harbors a very large genome (5.5–7 Mbp), and its relative size compared to other pathogens such as Bacillus subtilis (4.2 Mbp), Escherichia coli (4.6–5.3 Mbp) and Mycobacterium tuberculosis (4.4 Mbp) enables it to harbor significantly more virulent genes responsible for making it highly adaptable when interacting with a host [74,75,76,77]. To establish an aggressive infection, P. aeruginosa deploys different cell surface appendages to mediate physical host/pathogen interaction, enhances its quorum sensing capabilities, biofilm formation and the secretion of virulence factors [31,32,46,78,79]. Zot is one of several virulence factors secreted by P. aeruginosa. It is an evolutionary conserved toxin found in numerous GNB pathogens; these include, but are not limited to, P. aeruginosa, N. gonorrhoeae, N. meningitidis, A. baumannii, K. pneumoniae, E. coli, S. enterica, Y. pestis and V. cholerae. To date, Zot homologs have been identified strictly in GNB, without any trace in Gram-positive bacterial genomes. Zot’s association with the outer membrane of GNB is the restricting factor in its evolutionary path.
Zot is an outer membrane protein originally identified in the toxigenic Gram-negative bacteria, Vibrio cholerae. In the context of host–pathogen interaction, Zot serves as an enterotoxin capable of increasing intestinal epithelial tissue permeability [22,24,30]. Several reports show that the filamentous phage, CTXΦ, whose genome encodes a local stretch of several virulence factors (including the Zot gene), is responsible for mediating the horizontal transfer of this pathogenicity island to V. cholerae [23,25,26,27,80]. Interestingly, the high transmissible occurrence of the Zot gene along with ctxAB genes suggests their synergistic role in causing diarrhea typical of cholerae [24,80,81]. For example, the synergistic effect between Zot and cholerae toxin (CT) is displayed by the necessity of a detached epithelial cell rounding morphology (induced by Zot), for the maximal expulsion of electrolytes mediated by CT and the subsequent onset of acute dehydrating diarrhea commonly seen with V. cholerae infections [82].
Physically breaching epithelial cell barriers has profound effects on human health and disease, specifically in the context of disseminating infectious agents such as P. aeruginosa. Epithelial cell monolayers represent the foundational tissue barriers of the body [1,2,3,4,5,6,7,8,9]. Dermal abrasions, respiratory, enteric, oropharyngeal and genital mucosal epithelia are the primary portals of entry for most pathogens. Upon entry into a host, disease progression from a local infection to systemic dissemination requires the ability of the microbe to transmit across the mucosal epithelium and metastasize to distal anatomical sites. Studies show that the distribution of Zot receptor(s) coincides with the different permeating effects of the toxin on various types of epithelial tissue [22,24,29,83]. It is a bifunctional toxin responsible for enabling GNB pathogens to modulate their own paracellular transport between epithelial cell monolayers. Zot’s tight junctional regulatory properties are reversible, time and dose dependent, as well confined specifically to epithelial tissue [28]. Mechanistically, the binding of Zot to specific epithelial cell surface receptors initiates a signal transduction cascade that causes the disassembly of TJs, allowing the pathogen paracellular access to the basolateral host tissue [22,23,26,84]. In addition to its tight junctional regulatory properties, it has also been reported that Zot can regulate the post-translational modifications of cytoskeletal proteins [17,26,28]. The toxin induces the modifications of cytoskeletal complexes strategically localized to regulate the paracellular pathway between epithelial cells [26,82]. For example, ventilator-associated P. aeruginosa infections first establish a local pneumonic infection, where it promotes the accelerated decline in pulmonary function, followed by the subsequent paracellular passage between alveolar epithelial tissue (most likely mediated by Zot) and transition to a bacteremia state, where it disseminates throughout the lymphatic and/or circulatory systems causing severe sepsis [85,86,87,88,89].
It has become increasingly difficult to treat P. aeruginosa with conventional antibiotics. Its remarkable capacity to resist numerous antibiotics and use very high-level virulence mechanisms to counter antimicrobials and host defenses has made it imperative that alternative treatment strategies be developed to combat fatal P. aeruginosa infections [31,90,91]. In the context of infectious diseases, immunotherapy is a well-suited treatment modality that mitigates resistance, by harnessing a patient’s own immune defense mechanisms to fight disease more effectively [92,93,94]. It is well established that antibodies play a central role in the humeral immunity induced by vaccination, supported by TH cells [95,96]. Antibody responses are generally essential in preventing the establishment of disease [97,98], whereas, in recent years, it has become evident that cytotoxic T cells also play a major role in fighting an infection, by controlling and clearing an already established disease [99,100]. For example, there is ample evidence showing that individuals with inherited or acquired antibody deficiencies have an increased susceptibility to the acquisition of infection, whereas T-cell deficiency results in the failure to control a pathogen after an infection [101,102,103]. Treatment options such as native and passive immunization have made it possible to prevent or treat both infection cycles from occurring [93]. In either case, a “high value” antigen is required to induce a multilevel immune response that includes the terminal differentiation of various cells of the lymphoid origin responsible for driving both humoral and cell-mediated immune responses.
“High value” antigens are immunogens capable of polarizing both branches of the lymphoid linage, followed by the establishment of a long-lasting immune memory, with the minimal number of administrations. The key features of “high value” therapeutic antigens are that they are long enough to carry multiple, non-overlapping, high-affinity epitopes dispersed throughout the antigen and are rigid enough to enhance binding affinities to B-cell receptors and secreted antibodies. Compared to the structurally undefined antigens, a “high value” antigen has a considerable length to adopt a stable configuration. Furthermore, it is essential that the therapeutic coverage of the antigen span the maximum number of genetically diverse strains. Using proteomic-driven comparative phylogenetics, in conjunction with structural modeling, we have traced the horizontal passage of the virulence factor, Zot, and its relatedness among various GNB. Through our work, we report the identification of a “high value” intermembrane-associated stretch of 70 amino acids capable of inducing both B- and T-cell responses with high affinity towards a multitude of different P. aeruginosa genetic variants. The characterization of this antigen has revealed it to possess four non-overlapping MHC I epitopes with binding affinities above 90%. In the context of MHC II epitopes, our results reveal the identification of three non-overlapping antigenic determinants dispersed throughout the length of the antigen as well, with binding affinities above 70%. Lastly, the assessment of structural-based immunogenicity indicates that our newly identified transmembrane-associated 70-amino acid antigen adopts a stable β-pleated sheet conformation linked to a short helical configuration, further increasing its structural-based affinity to B-cell receptors and antibodies.
In silico techniques are becoming a crucial part of the drug discovery process. These bioinformatic tools provide us with the potential for predicting novel therapeutic targets, while minimizing the number of false positives during the drug development process. The clinical relevance of such an approach is that it enables us to employ phylogenetics to identify “high value” vaccine candidates for the treatment of various infectious diseases [104]. For example, due to the large number of different P. aeruginosa genetic variants, our in silico method identified a highly conserved region that is shared among all the different strains and not just a few targets. Our data suggest that reverse vaccinology can be used to identify cross-species antigens for therapeutic purposes [61,62,64]. This technique can not only be applied to bacteria, but also to other types of pathogens that share homologous ancestral origins [104,105,106,107].
The rapid emergence of pan-drug resistance amongst numerous bacterial pathogens has outpaced the development of novel antibiotics, and as a result, has led to our continued efforts to identify cutting-edge, antibiotic-independent treatment strategies. The in silico prediction of drug targets has emerged as a promising technology platform for biomedical research and development [106,108]. The extensive homology of Zot, shared amongst numerous GNB pathogens, serves as an ideal target for the development of multi-strain-driven vaccines for P. aeruginosa and numerous other GNB pathogens. The advantage of employing comparative proteomics, in conjunction with structural modeling, is that it has allowed the identification of an evolutionary conserved intermembrane-associated stretch of 70 amino acids that is structurally identical among all the P. aeruginosa genetic variants queried, irrespective of how homologous the sequence is between the different strains.
Our reverse vaccinology strategy, using a combination of proteomic-driven bioinformatic tools in conjunction with structural modeling, has the potential to be used as a universal vaccine design technique that spans many different pathogens such as bacterial, fungal, viral and parasitic. The combination of phylogenetics and structural drug design methods will pave the way for the identification of “high value” antigenic drug leads that can be used to protect against numerous different species of pathogens and their genetic variants [104,105,106,107,108]. Future perspectives include the generation of monoclonal antibodies raised against our newly identified “high value” vaccine candidates and assess their binding affinities in vitro and therapeutic efficacy in vivo.

4. Methods

4.1. UniProt Database Mining

The UniProt Knowledgebase provides users a high-quality and comprehensive set of protein sequences annotated with functional information. To fully understand the distribution of the Zot gene among GNB pathogens, we performed an extensive UniProt search with Zonula occludens toxin as the query (accessed 26 February 2024). Of the 284 predicted individual protein entities identified, the closest full-length matches (≥345 amino acids) to the V. cholerae Zot protein sequence were chosen. A total of 150 different protein entities and 35 species-specific bacteriophages were identified and chosen for our studies (Table 1). All the identified protein entities were distributed among eight different clinically relevant GNB pathogens: P. aeruginosa, V. cholerae, N. gonorrhoeae, N. meningitidis, A. baumannii, K. pneumoniae, E. coli, S. enterica and Y. pestis. It should be noted that the database mining results did not reveal the presence of Zot-like proteins associated with any Gram-positive bacteria [109,110].

4.2. NCBI BLAST and MUSCLE Algorithm

First, a tree was calculated by employing the MUSCLE algorithm, which counts the number of short sub-sequences (known as k-mers, k-tuples or words) that two sequences have in common, without constructing an alignment. In the second step, MUSCLE uses the tree to construct a progressive alignment. At each node of the binary tree, a pair-wise alignment is constructed, progressing leaves towards the root. The first alignment is made from two sequences. Later alignments included one of three different types: sequence–sequence, profile–sequence or profile–profile, where “profile” means the multiple alignment of the sequences under a given internal node of the tree. In conjunction with MUSCLE, we employed the Multiple Sequence Alignment Viewer Application (MSA), which is a web-based application that displays the graphical alignments generated by algorithms such as CLUSTALW, MUSCLE and alignments from NCBI BLAST. We viewed the alignments using the FASTA files generated by MUSCLE, UniProt and NCBI [65,111,112].

4.3. Backtranslation

In order to phylogenetically compare the nucleotide sequence homology among all the tested species-specific Zot protein sequences, a backtranslation approach was used. Backtranslation is a method of decoding an amino acid sequence into its corresponding codons. However, the degeneracy of the genome makes backtranslation very ambiguous, since multiple codons can represent the same amino acid. The most common strategy to overcome such hurdle is based on the imitation of codon usage within the target species. Accordingly, all the Zot protein sequences were backtranslated according to the species-specific codon optimization tools such as EMBOSS Backtranseq [113,114].

4.4. Immune Epitope Database and Analysis Resource (IEDB)

The IEDB was created to assist biomedical researchers in the development of new vaccines, diagnostics and therapeutics. The Analysis Resource is freely available to all researchers and provides access to a variety of epitope analysis and prediction tools. The tools include validated and benchmarked methods to predict MHC class I and class II binding. The predictions from these tools can be combined with tools predicting antigen processing, TCR recognition and B-cell epitope prediction. In addition, the resource contains a variety of secondary analysis tools that allow the researcher to calculate epitope conservation, population coverage and other relevant analytic variables. Predictions were obtained by using the 70-amino acid consensus sequence from strain A0A1C7BT03 [115,116].

4.5. SWISS-MODEL

SWISS-MODEL is an algorithm used for the automated comparative modeling of protein structures. In the “first approach mode” only an amino acid sequence of a protein is submitted to build a 3D model. Template selection, alignment and model building are completely automated by the server. In the “alignment mode”, the modeling process is based on a user-defined target–template alignment. The user specifies which sequence in the given alignment is the target sequence and which one corresponds to a structurally known protein chain from the ExPDB template library. The server will build the model based on the given alignment. Complex modeling tasks can be handled via the “project mode” using DeepView (Swiss-PdbViewer), an integrated sequence-to-structure workbench [117,118].

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original data presented in the study are openly available in Uniprot database. All accession numbers are posted in materials section.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Acloque, H.; Adams, M.S.; Fishwick, K.; Bronner-Fraser, M.; Nieto, M.A. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J. Clin. Investig. 2009, 119, 1438–1449. [Google Scholar] [CrossRef] [PubMed]
  2. Blanpain, C.; Horsley, V.; Fuchs, E. Epithelial stem cells: Turning over new leaves. Cell 2007, 128, 445–458. [Google Scholar] [CrossRef] [PubMed]
  3. Buckley, C.E.; St Johnston, D. Apical–basal polarity and the control of epithelial form and function. Nat. Rev. Mol. Cell Biol. 2022, 23, 559–577. [Google Scholar] [CrossRef] [PubMed]
  4. Duszyc, K.; Gomez, G.A.; Schroder, K.; Sweet, M.J.; Yap, A.S. In life there is death: How epithelial tissue barriers are preserved despite the challenge of apoptosis. Tissue Barriers 2017, 5, e1345353. [Google Scholar] [CrossRef] [PubMed]
  5. Lavker, R.; Sun, T. Epithelial stem cells: The eye provides a vision. Eye 2003, 17, 937–942. [Google Scholar] [CrossRef] [PubMed]
  6. Peterson, L.W.; Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14, 141–153. [Google Scholar] [CrossRef] [PubMed]
  7. Plikus, M.V.; Gay, D.L.; Treffeisen, E.; Wang, A.; Supapannachart, R.J.; Cotsarelis, G. Epithelial stem cells and implications for wound repair. Semin. Cell Dev. Biol. 2012, 23, 946–953. [Google Scholar] [CrossRef] [PubMed]
  8. Shashikanth, N.; Yeruva, S.; Ong, M.; Odenwald, M.A.; Pavlyuk, R.; Turner, J.R. Epithelial organization: The gut and beyond. Compr. Physiol. 2017, 7, 1497–1518. [Google Scholar] [PubMed]
  9. Tadeu, A.M.B.; Horsley, V. Epithelial stem cells in adult skin. Curr. Top. Dev. Biol. 2014, 107, 109–131. [Google Scholar] [PubMed]
  10. Hudspeth, A. Establishment of tight junctions between epithelial cells. Proc. Natl. Acad. Sci. USA 1975, 72, 2711–2713. [Google Scholar] [CrossRef]
  11. Anderson, J.M.; Van Itallie, C.M. Physiology and function of the tight junction. Cold Spring Harb. Perspect. Biol. 2009, 1, a002584. [Google Scholar] [CrossRef] [PubMed]
  12. Shin, K.; Fogg, V.C.; Margolis, B. Tight junctions and cell polarity. Annu. Rev. Cell Dev. Biol. 2006, 22, 207–235. [Google Scholar] [CrossRef] [PubMed]
  13. Tsukita, S.; Yamazaki, Y.; Katsuno, T.; Tamura, A. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 2008, 27, 6930–6938. [Google Scholar] [CrossRef] [PubMed]
  14. Díaz-Coránguez, M.; Liu, X.; Antonetti, D.A. Tight junctions in cell proliferation. Int. J. Mol. Sci. 2019, 20, 5972. [Google Scholar] [CrossRef] [PubMed]
  15. Förster, C. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 2008, 130, 55–70. [Google Scholar] [CrossRef] [PubMed]
  16. Kyuno, D.; Takasawa, A.; Kikuchi, S.; Takemasa, I.; Osanai, M.; Kojima, T. Role of tight junctions in the epithelial-to-mesenchymal transition of cancer cells. Biochim. Biophys. Acta (BBA)-Biomembr. 2021, 1863, 183503. [Google Scholar] [CrossRef]
  17. Matter, K.; Balda, M.S. Epithelial tight junctions, gene expression and nucleo-junctional interplay. J. Cell Sci. 2007, 120, 1505–1511. [Google Scholar] [CrossRef] [PubMed]
  18. Niessen, C.M. Tight junctions/adherens junctions: Basic structure and function. J. Investig. Dermatol. 2007, 127, 2525–2532. [Google Scholar] [CrossRef] [PubMed]
  19. Paradis, T.; Bègue, H.; Basmaciyan, L.; Dalle, F.; Bon, F. Tight junctions as a key for pathogens invasion in intestinal epithelial cells. Int. J. Mol. Sci. 2021, 22, 2506. [Google Scholar] [CrossRef] [PubMed]
  20. Van Itallie, C.M.; Anderson, J.M. Architecture of tight junctions and principles of molecular composition. Semin. Cell Dev. Biol. 2014, 36, 157–165. [Google Scholar] [CrossRef]
  21. Zihni, C.; Balda, M.S.; Matter, K. Signalling at tight junctions during epithelial differentiation and microbial pathogenesis. J. Cell Sci. 2014, 127, 3401–3413. [Google Scholar] [CrossRef] [PubMed]
  22. Di Pierro, M.; Lu, R.; Uzzau, S.; Wang, W.; Margaretten, K.; Pazzani, C.; Maimone, F.; Fasano, A. Zonula occludens toxin structure-function analysis: Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J. Biol. Chem. 2001, 276, 19160–19165. [Google Scholar] [CrossRef] [PubMed]
  23. Fasano, A. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann. N. Y. Acad. Sci. 2000, 915, 214–222. [Google Scholar] [CrossRef] [PubMed]
  24. Karasawa, T.; Mihara, T.; Kurazono, H.; Nair, G.B.; Garg, S.; Ramamurthy, T.; Takeda, Y. Distribution of the zot (zonula occludens toxin) gene among strains of Vibrio cholerae 01 and non-01. FEMS Microbiol. Lett. 1993, 106, 143–145. [Google Scholar] [CrossRef] [PubMed]
  25. Ma, L.; Roux, S.; Hua, X.; Wang, Y.; Loh, B.; Leptihn, S. From motor protein to toxin: Mutations in the zonula occludens toxin (Zot) of Vibrio cholerae phage CTXϕ suggest a loss of phage assembly function. bioRxiv 2022. [Google Scholar] [CrossRef]
  26. Uzzau, S.; Cappuccinelli, P.; Fasano, A. Expression of Vibrio cholerae zonula occludens toxin and analysis of its subcellular localization. Microb. Pathog. 1999, 27, 377–385. [Google Scholar] [CrossRef] [PubMed]
  27. Pant, A.; Das, B.; Bhadra, R.K. CTX phage of Vibrio cholerae: Genomics and applications. Vaccine 2020, 38, A7–A12. [Google Scholar] [CrossRef] [PubMed]
  28. Fasano, A.; Fiorentini, C.; Donelli, G.; Uzzau, S.; Kaper, J.; Margaretten, K.; Ding, X.; Guandalini, S.; Comstock, L.; Goldblum, S. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J. Clin. Investig. 1995, 96, 710–720. [Google Scholar] [CrossRef]
  29. Karyekar, C.S.; Fasano, A.; Raje, S.; Lu, R.; Dowling, T.C.; Eddington, N.D. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J. Pharm. Sci. 2003, 92, 414–423. [Google Scholar] [CrossRef] [PubMed]
  30. Lee, A.; White, N.; van der Walle, C.F. The intestinal zonula occludens toxin (ZOT) receptor recognises non-native ZOT conformers and localises to the intercellular contacts. FEBS Lett. 2003, 555, 638–642. [Google Scholar] [CrossRef] [PubMed]
  31. Qin, S.; Xiao, W.; Zhou, C.; Pu, Q.; Deng, X.; Lan, L.; Liang, H.; Song, X.; Wu, M. Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct. Target. Ther. 2022, 7, 199. [Google Scholar] [CrossRef] [PubMed]
  32. Bleves, S.; Viarre, V.; Salacha, R.; Michel, G.P.; Filloux, A.; Voulhoux, R. Protein secretion systems in Pseudomonas aeruginosa: A wealth of pathogenic weapons. Int. J. Med. Microbiol. 2010, 300, 534–543. [Google Scholar] [CrossRef] [PubMed]
  33. Horna, G.; Ruiz, J. Type 3 secretion system of Pseudomonas aeruginosa. Microbiol. Res. 2021, 246, 126719. [Google Scholar] [CrossRef] [PubMed]
  34. Wu, T.; Zhang, Z.; Li, T.; Dong, X.; Wu, D.; Zhu, L.; Xu, K.; Zhang, Y. The type III secretion system facilitates systemic infections of Pseudomonas aeruginosa in the clinic. Microbiol. Spectr. 2024, 12, e02224-23. [Google Scholar] [CrossRef] [PubMed]
  35. Elsahn, A.; del Mar Cendra, M.; Humbert, M.V.; Christodoulides, M.; Dua, H.; Hossain, P. Pseudomonas aeruginosa host-pathogen interactions in human corneal infection models. J. EuCornea 2020, 7, 8–16. [Google Scholar] [CrossRef]
  36. Liao, C.; Huang, X.; Wang, Q.; Yao, D.; Lu, W. Virulence factors of Pseudomonas aeruginosa and antivirulence strategies to combat its drug resistance. Front. Cell. Infect. Microbiol. 2022, 12, 926758. [Google Scholar] [CrossRef] [PubMed]
  37. Lee, V.T.; Smith, R.S.; Tümmler, B.; Lory, S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect. Immun. 2005, 73, 1695–1705. [Google Scholar] [CrossRef] [PubMed]
  38. Burstein, D.; Satanower, S.; Simovitch, M.; Belnik, Y.; Zehavi, M.; Yerushalmi, G.; Ben-Aroya, S.; Pupko, T.; Banin, E. Novel type III effectors in Pseudomonas aeruginosa. mBio 2015, 6, e00161-15. [Google Scholar] [CrossRef] [PubMed]
  39. Whitchurch, C.B.; Leech, A.J.; Young, M.D.; Kennedy, D.; Sargent, J.L.; Bertrand, J.J.; Semmler, A.B.; Mellick, A.S.; Martin, P.R.; Alm, R.A. Characterization of a complex chemosensory signal transduction system which controls twitching motility in Pseudomonas aeruginosa. Mol. Microbiol. 2004, 52, 873–893. [Google Scholar] [CrossRef] [PubMed]
  40. Overhage, J.; Bains, M.; Brazas, M.D.; Hancock, R.E. Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. Am. Soc. Microbiol. 2008, 190, 2671–2679. [Google Scholar]
  41. Thi, M.T.T.; Wibowo, D.; Rehm, B.H. Pseudomonas aeruginosa biofilms. Int. J. Mol. Sci. 2020, 21, 8671. [Google Scholar] [CrossRef] [PubMed]
  42. Burrows, L.L. Pseudomonas aeruginosa twitching motility: Type IV pili in action. Annu. Rev. Microbiol. 2012, 66, 493–520. [Google Scholar] [CrossRef] [PubMed]
  43. Rashid, M.H.; Rumbaugh, K.; Passador, L.; Davies, D.G.; Hamood, A.N.; Iglewski, B.H.; Kornberg, A. Polyphosphate kinase is essential for biofilm development, quorum sensing, and virulence of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 2000, 97, 9636–9641. [Google Scholar] [CrossRef] [PubMed]
  44. Basso, P.; Ragno, M.; Elsen, S.; Reboud, E.; Golovkine, G.; Bouillot, S.; Huber, P.; Lory, S.; Faudry, E.; Attrée, I. Pseudomonas aeruginosa pore-forming exolysin and type IV pili cooperate to induce host cell lysis. mBio 2017, 8, e02250-16. [Google Scholar] [CrossRef]
  45. Bertrand, Q.; Job, V.; Maillard, A.P.; Imbert, L.; Teulon, J.-M.; Favier, A.; Pellequer, J.-L.; Huber, P.; Attree, I.; Dessen, A. Exolysin (ExlA) from Pseudomonas aeruginosa punctures holes into target membranes using a molten globule domain. J. Mol. Biol. 2020, 432, 4466–4480. [Google Scholar] [CrossRef] [PubMed]
  46. Bomberger, J.M.; Ye, S.; MacEachran, D.P.; Koeppen, K.; Barnaby, R.L.; O’Toole, G.A.; Stanton, B.A. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 2011, 7, e1001325. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, P.V. Extracellular toxins of Pseudomonas aeruginosa. J. Infect. Dis. 1974, 130, S94–S99. [Google Scholar] [CrossRef]
  48. Smith, R.S.; Iglewski, B.H. P. aeruginosa quorum-sensing systems and virulence. Curr. Opin. Microbiol. 2003, 6, 56–60. [Google Scholar] [CrossRef] [PubMed]
  49. Kostylev, M.; Kim, D.Y.; Smalley, N.E.; Salukhe, I.; Greenberg, E.P.; Dandekar, A.A. Evolution of the Pseudomonas aeruginosa quorum-sensing hierarchy. Proc. Natl. Acad. Sci. USA 2019, 116, 7027–7032. [Google Scholar] [CrossRef] [PubMed]
  50. Rasko, D.A.; Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 2010, 9, 117–128. [Google Scholar] [CrossRef] [PubMed]
  51. Heras, B.; Scanlon, M.J.; Martin, J.L. Targeting virulence not viability in the search for future antibacterials. Br. J. Clin. Pharmacol. 2015, 79, 208–215. [Google Scholar] [CrossRef] [PubMed]
  52. Khan, H.A.; Baig, F.K.; Mehboob, R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac. J. Trop. Biomed. 2017, 7, 478–482. [Google Scholar] [CrossRef]
  53. Ikuta, K.S.; Swetschinski, L.R.; Aguilar, G.R.; Sharara, F.; Mestrovic, T.; Gray, A.P.; Weaver, N.D.; Wool, E.E.; Han, C.; Hayoon, A.G. Global mortality associated with 33 bacterial pathogens in 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022, 400, 2221–2248. [Google Scholar] [CrossRef] [PubMed]
  54. Reynolds, D.; Kollef, M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: An update. Drugs 2021, 81, 2117–2131. [Google Scholar] [CrossRef] [PubMed]
  55. Iglewski, B.H. Chapter 27 pseudomonas. In Medical Microbiology, 4th ed.; University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996. [Google Scholar]
  56. Migiyama, Y.; Yanagihara, K.; Kaku, N.; Harada, Y.; Yamada, K.; Nagaoka, K.; Morinaga, Y.; Akamatsu, N.; Matsuda, J.; Izumikawa, K. Pseudomonas aeruginosa bacteremia among immunocompetent and immunocompromised patients: Relation to initial antibiotic therapy and survival. Jpn. J. Infect. Dis. 2016, 69, 91–96. [Google Scholar] [CrossRef] [PubMed]
  57. Wilson, M.G.; Pandey, S. Pseudomonas aeruginosa; StatPearls Publishing: Treasure Island, FL, USA, 2020. [Google Scholar]
  58. Middleton, M.A.; Layeghifard, M.; Klingel, M.; Stanojevic, S.; Yau, Y.C.; Zlosnik, J.E.; Coriati, A.; Ratjen, F.A.; Tullis, E.D.; Stephenson, A. Epidemiology of clonal Pseudomonas aeruginosa infection in a Canadian cystic fibrosis population. Ann. Am. Thorac. Soc. 2018, 15, 827–836. [Google Scholar] [CrossRef] [PubMed]
  59. Bassetti, M.; Vena, A.; Croxatto, A.; Righi, E.; Guery, B. How to manage Pseudomonas aeruginosa infections. Drugs Context 2018, 7, 212527. [Google Scholar] [CrossRef] [PubMed]
  60. Nandy, A.; Basak, S.C. Bioinformatics in design of antiviral vaccines. Encycl. Biomed. Eng. 2019, 280–290. [Google Scholar] [CrossRef]
  61. Delany, I.; Rappuoli, R.; Seib, K.L. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb. Perspect. Med. 2013, 3, a012476. [Google Scholar] [CrossRef] [PubMed]
  62. Bagnoli, F.; Galgani, I.; Vadivelu, V.K.; Phogat, S. Reverse development of vaccines against antimicrobial-resistant pathogens. npj Vaccines 2024, 9, 71. [Google Scholar] [CrossRef] [PubMed]
  63. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.; Bartolini, E.; Capecchi, B. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287, 1816–1820. [Google Scholar] [CrossRef] [PubMed]
  64. Rappuoli, R. Reverse vaccinology. Curr. Opin. Microbiol. 2000, 3, 445–450. [Google Scholar] [CrossRef] [PubMed]
  65. Edgar, R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32, 1792–1797. [Google Scholar] [CrossRef] [PubMed]
  66. Mishra, M.; Panda, S.; Barik, S.; Sarkar, A.; Singh, D.V.; Mohapatra, H. Antibiotic resistance profile, outer membrane proteins, virulence factors and genome sequence analysis reveal clinical isolates of Enterobacter are potential pathogens compared to environmental isolates. Front. Cell. Infect. Microbiol. 2020, 10, 54. [Google Scholar] [CrossRef] [PubMed]
  67. Kovjazin, R.; Volovitz, I.; Daon, Y.; Vider-Shalit, T.; Azran, R.; Tsaban, L.; Carmon, L.; Louzoun, Y. Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development. Mol. Immunol. 2011, 48, 1009–1018. [Google Scholar] [CrossRef] [PubMed]
  68. Bilderbeek, R.J.; Baranov, M.V.; van den Bogaart, G.; Bianchi, F. Transmembrane Helices Are an Over-Presented and Evolutionarily Conserved Source of Major Histocompatibility Complex Class I and II Epitopes. Front. Immunol. 2022, 12, 763044. [Google Scholar] [CrossRef] [PubMed]
  69. Marinaro, M.; di Tommaso, A.; Uzzau, S.; Fasano, A.; de Magistris, M.T. Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect. Immun. 1999, 67, 1287–1291. [Google Scholar] [CrossRef] [PubMed]
  70. Marinaro, M.; Fasano, A.; De Magistris, M.T. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect. Immun. 2003, 71, 1897–1902. [Google Scholar] [CrossRef] [PubMed]
  71. Butler, M.S.; Henderson, I.R.; Capon, R.J.; Blaskovich, M.A. Antibiotics in the clinical pipeline as of December 2022. J. Antibiot. 2023, 76, 431–473. [Google Scholar] [CrossRef] [PubMed]
  72. Butler, M.S.; Gigante, V.; Sati, H.; Paulin, S.; Al-Sulaiman, L.; Rex, J.H.; Fernandes, P.; Arias, C.A.; Paul, M.; Thwaites, G.E. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: Despite progress, more action is needed. Antimicrob. Agents Chemother. 2022, 66, e01991-21. [Google Scholar] [CrossRef] [PubMed]
  73. Kostyanev, T.; Can, F. The global crisis of antimicrobial resistance. In Antimicrobial Stewardship; Elsevier: Amsterdam, The Netherlands, 2017; pp. 3–12. [Google Scholar]
  74. Kunst, F.j.; Ogasawara, N.; Moszer, I.; Albertini, A.; Alloni, G.; Azevedo, V.; Bertero, M.; Bessières, P.; Bolotin, A.; Borchert, S. The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature 1997, 390, 249–256. [Google Scholar] [CrossRef] [PubMed]
  75. Rode, C.K.; Melkerson-Watson, L.J.; Johnson, A.T.; Bloch, C.A. Type-specific contributions to chromosome size differences in Escherichia coli. Infect. Immun. 1999, 67, 230–236. [Google Scholar] [CrossRef] [PubMed]
  76. Dohal, M.; Porvaznik, I.; Kusnir, P.; Mokry, J. Whole-Genome Sequencing in Relation to Resistance of Mycobacterium tuberculosis. Acta Medica Martiniana 2019, 19, 12–21. [Google Scholar] [CrossRef]
  77. Klockgether, J.; Cramer, N.; Wiehlmann, L.; Davenport, C.F.; Tümmler, B. Pseudomonas aeruginosa genomic structure and diversity. Front. Microbiol. 2011, 2, 10805. [Google Scholar] [CrossRef] [PubMed]
  78. Conrad, J.C.; Gibiansky, M.L.; Jin, F.; Gordon, V.D.; Motto, D.A.; Mathewson, M.A.; Stopka, W.G.; Zelasko, D.C.; Shrout, J.D.; Wong, G.C. Flagella and pili-mediated near-surface single-cell motility mechanisms in P. aeruginosa. Biophys. J. 2011, 100, 1608–1616. [Google Scholar] [CrossRef] [PubMed]
  79. Sadikot, R.T.; Blackwell, T.S.; Christman, J.W.; Prince, A.S. Pathogen–host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 2005, 171, 1209–1223. [Google Scholar] [CrossRef] [PubMed]
  80. Rivera, I.; Chowdhury, M.; Sanchez, P.; Sato, M.; Huq, A.; Colwell, R.; Martins, M. Detection of cholera (ctx) and zonula occludens (zot) toxin genes in Vibrio cholerae O1, O139 and non-O1 strains. World J. Microbiol. Biotechnol. 1995, 11, 572–577. [Google Scholar] [CrossRef] [PubMed]
  81. Johnson, J.A.; Morris, J., Jr.; Kaper, J. Gene encoding zonula occludens toxin (zot) does not occur independently from cholera enterotoxin genes (ctx) in Vibrio cholerae. J. Clin. Microbiol. 1993, 31, 732–733. [Google Scholar] [CrossRef] [PubMed]
  82. Fasano, A.; Baudry, B.; Pumplin, D.W.; Wasserman, S.S.; Tall, B.D.; Ketley, J.M.; Kaper, J. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc. Natl. Acad. Sci. USA 1991, 88, 5242–5246. [Google Scholar] [CrossRef]
  83. Cox, D.S.; Gao, H.; Raje, S.; Scott, K.R.; Eddington, N.D. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur. J. Pharm. Biopharm. 2001, 52, 145–150. [Google Scholar] [CrossRef] [PubMed]
  84. Uzzau, S.; Lu, R.; Wang, W.; Fiore, C.; Fasano, A. Purification and preliminary characterization of the zonula occludens toxin receptor from human (CaCo2) and murine (IEC6) intestinal cell lines. FEMS Microbiol. Lett. 2001, 194, 1–5. [Google Scholar] [CrossRef] [PubMed]
  85. Nomura, K.; Obata, K.; Keira, T.; Miyata, R.; Hirakawa, S.; Takano, K.-i.; Kohno, T.; Sawada, N.; Himi, T.; Kojima, T. Pseudomonas aeruginosa elastase causes transient disruption of tight junctions and downregulation of PAR-2 in human nasal epithelial cells. Respir. Res. 2014, 15, 21. [Google Scholar] [CrossRef] [PubMed]
  86. Golovkine, G.; Faudry, E.; Bouillot, S.; Elsen, S.; Attrée, I.; Huber, P. Pseudomonas aeruginosa transmigrates at epithelial cell-cell junctions, exploiting sites of cell division and senescent cell extrusion. PLoS Pathog. 2016, 12, e1005377. [Google Scholar] [CrossRef]
  87. Muggeo, A.; Coraux, C.; Guillard, T. Current concepts on Pseudomonas aeruginosa interaction with human airway epithelium. PLoS Pathog. 2023, 19, e1011221. [Google Scholar] [CrossRef] [PubMed]
  88. Ng, Q.X.; Ong, N.Y.; Lee, D.Y.X.; Yau, C.E.; Lim, Y.L.; Kwa, A.L.H.; Tan, B.H. Trends in Pseudomonas aeruginosa (P. aeruginosa) bacteremia during the COVID-19 pandemic: A systematic review. Antibiotics 2023, 12, 409. [Google Scholar] [CrossRef] [PubMed]
  89. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.-J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019, 37, 177–192. [Google Scholar] [CrossRef]
  90. Kunz Coyne, A.J.; El Ghali, A.; Holger, D.; Rebold, N.; Rybak, M.J. Therapeutic strategies for emerging multidrug-resistant Pseudomonas aeruginosa. Infect. Dis. Ther. 2022, 11, 661–682. [Google Scholar] [CrossRef] [PubMed]
  91. Horcajada, J.P.; Montero, M.; Oliver, A.; Sorlí, L.; Luque, S.; Gómez-Zorrilla, S.; Benito, N.; Grau, S. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin. Microbiol. Rev. 2019, 32, e00031-19. [Google Scholar] [CrossRef]
  92. Sousa, S.A.; Seixas, A.M.; Marques, J.M.; Leitão, J.H. Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections. Vaccines 2021, 9, 670. [Google Scholar] [CrossRef]
  93. Döring, G.; Pier, G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008, 26, 1011–1024. [Google Scholar] [CrossRef]
  94. Killough, M.; Rodgers, A.M.; Ingram, R.J. Pseudomonas aeruginosa: Recent advances in vaccine development. Vaccines 2022, 10, 1100. [Google Scholar] [CrossRef] [PubMed]
  95. Clem, A.S. Fundamentals of vaccine immunology. J. Glob. Infect. Dis. 2011, 3, 73–78. [Google Scholar] [CrossRef] [PubMed]
  96. Shah, N.; Ershler, W. Immune System. In Encyclopedia of Gerontology; Elsevier/Academic Press: Amsterdam, The Netherlands, 2007; pp. 742–749. Available online: https://search.library.ucla.edu/discovery/openurl?institution=01UCS_LAL&vid=01UCS_LAL:UCLA&aulast=Shah&id=doi:10.1016%2FB0-12-370870-2%2F00097-4&auinit=NS&atitle=Immune%20System&sid=google (accessed on 11 June 2024).
  97. Lu, L.L.; Suscovich, T.J.; Fortune, S.M.; Alter, G. Beyond binding: Antibody effector functions in infectious diseases. Nat. Rev. Immunol. 2018, 18, 46–61. [Google Scholar] [CrossRef] [PubMed]
  98. Sebina, I.; Pepper, M. Humoral immune responses to infection: Common mechanisms and unique strategies to combat pathogen immune evasion tactics. Curr. Opin. Immunol. 2018, 51, 46–54. [Google Scholar] [CrossRef] [PubMed]
  99. Tian, L.; Zhou, W.; Wu, X.; Hu, Z.; Qiu, L.; Zhang, H.; Chen, X.; Zhang, S.; Lu, Z. CTLs: Killers of intracellular bacteria. Front. Cell. Infect. Microbiol. 2022, 12, 967679. [Google Scholar] [CrossRef] [PubMed]
  100. Thakur, A.; Mikkelsen, H.; Jungersen, G. Intracellular pathogens: Host immunity and microbial persistence strategies. J. Immunol. Res. 2019, 2019, 1356540. [Google Scholar] [CrossRef] [PubMed]
  101. Fried, A.J.; Bonilla, F.A. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin. Microbiol. Rev. 2009, 22, 396–414. [Google Scholar] [CrossRef] [PubMed]
  102. Pollard, A.J.; Bijker, E.M. A guide to vaccinology: From basic principles to new developments. Nat. Rev. Immunol. 2021, 21, 83–100. [Google Scholar] [CrossRef] [PubMed]
  103. Sun, L.; Su, Y.; Jiao, A.; Wang, X.; Zhang, B. T cells in health and disease. Signal Transduct. Target. Ther. 2023, 8, 235. [Google Scholar] [PubMed]
  104. Abay, Z.; Sadikalieva, S.; Shorayeva, K.; Yespembetov, B.; Sarmykova, M.; Jekebekov, K.; Tokkarina, G.; Absatova, Z.; Kalimolda, E.; Shayakhmetov, Y. Phylogenetic analysis of prospective M. bovis antigens with the aim of developing candidate vaccines for bovine tuberculosis. J. Genet. Eng. Biotechnol. 2023, 21, 99. [Google Scholar] [CrossRef]
  105. C Ashton, J. Phylogenetic methods in drug discovery. Curr. Drug Discov. Technol. 2013, 10, 255–262. [Google Scholar] [CrossRef] [PubMed]
  106. Agamah, F.E.; Mazandu, G.K.; Hassan, R.; Bope, C.D.; Thomford, N.E.; Ghansah, A.; Chimusa, E.R. Computational/in silico methods in drug target and lead prediction. Brief. Bioinform. 2020, 21, 1663–1675. [Google Scholar] [CrossRef] [PubMed]
  107. Verma, N.; Puri, A.; Essuman, E.; Skelton, R.; Anantharaman, V.; Zheng, H.; White, S.; Gunalan, K.; Takeda, K.; Bajpai, S. Antigen discovery, bioinformatics and biological characterization of novel immunodominant Babesia microti antigens. Sci. Rep. 2020, 10, 9598. [Google Scholar] [CrossRef] [PubMed]
  108. Zhang, X.; Wu, F.; Yang, N.; Zhan, X.; Liao, J.; Mai, S.; Huang, Z. In silico methods for identification of potential therapeutic targets. Interdiscip. Sci. Comput. Life Sci. 2022, 14, 285–310. [Google Scholar] [CrossRef] [PubMed]
  109. The UniProt Consortium. UniProt: The universal protein knowledgebase in 2023. Nucleic Acids Res. 2023, 51, D523–D531. [Google Scholar] [CrossRef] [PubMed]
  110. Lussi, Y.C.; Magrane, M.; Martin, M.J.; Orchard, S.; UniProt Consortium. Searching and navigating UniProt databases. Curr. Protoc. 2023, 3, e700. [Google Scholar] [CrossRef] [PubMed]
  111. Boratyn, G.M.; Camacho, C.; Cooper, P.S.; Coulouris, G.; Fong, A.; Ma, N.; Madden, T.L.; Matten, W.T.; McGinnis, S.D.; Merezhuk, Y. BLAST: A more efficient report with usability improvements. Nucleic Acids Res. 2013, 41, W29–W33. [Google Scholar] [CrossRef] [PubMed]
  112. Johnson, M.; Zaretskaya, I.; Raytselis, Y.; Merezhuk, Y.; McGinnis, S.; Madden, T.L. NCBI BLAST: A better web interface. Nucleic Acids Res. 2008, 36 (Suppl. S2), W5–W9. [Google Scholar] [CrossRef] [PubMed]
  113. Chojnacki, S.; Cowley, A.; Lee, J.; Foix, A.; Lopez, R. Programmatic access to bioinformatics tools from EMBL-EBI update: 2017. Nucleic Acids Res. 2017, 45, W550–W553. [Google Scholar] [CrossRef] [PubMed]
  114. Li, W.; Cowley, A.; Uludag, M.; Gur, T.; McWilliam, H.; Squizzato, S.; Park, Y.M.; Buso, N.; Lopez, R. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res. 2015, 43, W580–W584. [Google Scholar] [CrossRef]
  115. Fleri, W.; Paul, S.; Dhanda, S.K.; Mahajan, S.; Xu, X.; Peters, B.; Sette, A. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front. Immunol. 2017, 8, 250318. [Google Scholar] [CrossRef] [PubMed]
  116. Kim, Y.; Ponomarenko, J.; Zhu, Z.; Tamang, D.; Wang, P.; Greenbaum, J.; Lundegaard, C.; Sette, A.; Lund, O.; Bourne, P.E. Immune epitope database analysis resource. Nucleic Acids Res. 2012, 40, W525–W530. [Google Scholar] [CrossRef] [PubMed]
  117. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M.C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003, 31, 3381–3385. [Google Scholar] [CrossRef] [PubMed]
  118. Waterhouse, A.; Bertoni, M.; Bienert, S.; Studer, G.; Tauriello, G.; Gumienny, R.; Heer, F.T.; de Beer, T.A.P.; Rempfer, C.; Bordoli, L. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018, 46, W296–W303. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Numerous GNB genomes harbor evolutionarily conserved Zot homologs. Table representing 150 (UniProt confirmed) protein entities and their corresponding bacteriophages that harbor the Zot gene. Distribution among all pathogens falls under eight different GNB species (A). Proteomic-driven phylogenetics of eight GNB and their corresponding bacteriophages reveal that they are distributed among four clades (red circles # 1–4) and one outgroup lineage labeled # 5 (B). Phylogenetic relationship among species-specific bacteriophages falls into seven clads (C).
Figure 1. Numerous GNB genomes harbor evolutionarily conserved Zot homologs. Table representing 150 (UniProt confirmed) protein entities and their corresponding bacteriophages that harbor the Zot gene. Distribution among all pathogens falls under eight different GNB species (A). Proteomic-driven phylogenetics of eight GNB and their corresponding bacteriophages reveal that they are distributed among four clades (red circles # 1–4) and one outgroup lineage labeled # 5 (B). Phylogenetic relationship among species-specific bacteriophages falls into seven clads (C).
Toxins 16 00271 g001
Figure 2. Phylogenetic tracing of P. aeruginosa-encoded Zot reveals a high degree of homology shared among both nucleotide and amino acid sequences. Nucleic acid-based phylogram of 32 different strains distributed among 21 unique clusters and 14 different clads (A). Nucleotide-based percentage homology and query coverage among different variants (B). Schematic representation of homo- (gray) and heterogeneous (red) sequences of the Zot gene, among all genetically diverse strains (C). Amino acid-based phylogram reveals 32 different strains distributed among 23 unique clusters and 11 different clads (D). Proteomic-based phylogenetic tracing of Zot among different strains shows varying degrees of homology, ranging from 20 to 100% identity (E). Percentage identity is calculated as the number of matches in an alignment row relative to the alignment length, where the alignment length is either the length as determined by MUSCLE-specific BLAST alignment or the aligned sequence length minus any gaps (for all other alignments). Percentage coverage is calculated as the number of aligned nucleotides or residues in an alignment row relative to the aligned length of the anchor or consensus sequence. Orange circles represent each clade.
Figure 2. Phylogenetic tracing of P. aeruginosa-encoded Zot reveals a high degree of homology shared among both nucleotide and amino acid sequences. Nucleic acid-based phylogram of 32 different strains distributed among 21 unique clusters and 14 different clads (A). Nucleotide-based percentage homology and query coverage among different variants (B). Schematic representation of homo- (gray) and heterogeneous (red) sequences of the Zot gene, among all genetically diverse strains (C). Amino acid-based phylogram reveals 32 different strains distributed among 23 unique clusters and 11 different clads (D). Proteomic-based phylogenetic tracing of Zot among different strains shows varying degrees of homology, ranging from 20 to 100% identity (E). Percentage identity is calculated as the number of matches in an alignment row relative to the alignment length, where the alignment length is either the length as determined by MUSCLE-specific BLAST alignment or the aligned sequence length minus any gaps (for all other alignments). Percentage coverage is calculated as the number of aligned nucleotides or residues in an alignment row relative to the aligned length of the anchor or consensus sequence. Orange circles represent each clade.
Toxins 16 00271 g002aToxins 16 00271 g002b
Figure 3. Identification of an evolutionary conserved stretch of 70 amino acids, among different P. aeruginosa strains, is located in the mid-left section of the Zot protein. The top view shows the length of amino acid coverage in the alignment. Positions where most sequences are homologous to the consensus sequence are colored in red, and positions that contain mismatches are colored in gray. Gaps are indicated with a faint red line, and insertions relative to the anchor sequence are indicated by blue (A). Amino acid sequence of evolutionarily conserved stretch of 70 Amino acids, encoded by different P. aeruginosa genetic variants (B). Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged].
Figure 3. Identification of an evolutionary conserved stretch of 70 amino acids, among different P. aeruginosa strains, is located in the mid-left section of the Zot protein. The top view shows the length of amino acid coverage in the alignment. Positions where most sequences are homologous to the consensus sequence are colored in red, and positions that contain mismatches are colored in gray. Gaps are indicated with a faint red line, and insertions relative to the anchor sequence are indicated by blue (A). Amino acid sequence of evolutionarily conserved stretch of 70 Amino acids, encoded by different P. aeruginosa genetic variants (B). Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged].
Toxins 16 00271 g003
Figure 4. Annotative comparison of Zot, between V. cholerae and P. aeruginosa, reveals that our newly identified antigen is associated with the transmembrane domain. Stretch of 70 amino acid antigen (blue shading) is associated with the outer transmembrane (gray shading) of P. aeruginosa. C-terminus contains the cleaved toxicogenic fragment (yellow shading). A P-loop domain (gray shading) is found in V. cholerae to be present within the newly identified “high value” antigen. [Zot_VIBC, V. cholerae; A0A1C7BT03, P. aeruginosa]. Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged]. [conserved identical sequence (*); conserved mutation (:); semiconservative mutation (.)].
Figure 4. Annotative comparison of Zot, between V. cholerae and P. aeruginosa, reveals that our newly identified antigen is associated with the transmembrane domain. Stretch of 70 amino acid antigen (blue shading) is associated with the outer transmembrane (gray shading) of P. aeruginosa. C-terminus contains the cleaved toxicogenic fragment (yellow shading). A P-loop domain (gray shading) is found in V. cholerae to be present within the newly identified “high value” antigen. [Zot_VIBC, V. cholerae; A0A1C7BT03, P. aeruginosa]. Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged]. [conserved identical sequence (*); conserved mutation (:); semiconservative mutation (.)].
Toxins 16 00271 g004
Figure 5. Using the Immune Epitope Database (IEDB), we have identified several high-affinity epitopes capable of targeting multiple P. aeruginosa genetic variants. These tables display the sequences extracted from the 70-amino acid “high value” antigen input sequence. Each row in this table corresponds to one peptide binding prediction. MHC-1 (A); MHC-II (B); B-cell Peptides (C). The columns contain the allele that the prediction was made for, the position of the peptide in the input sequences, the length of the peptide, the peptide sequence, and the predicted affinity.
Figure 5. Using the Immune Epitope Database (IEDB), we have identified several high-affinity epitopes capable of targeting multiple P. aeruginosa genetic variants. These tables display the sequences extracted from the 70-amino acid “high value” antigen input sequence. Each row in this table corresponds to one peptide binding prediction. MHC-1 (A); MHC-II (B); B-cell Peptides (C). The columns contain the allele that the prediction was made for, the position of the peptide in the input sequences, the length of the peptide, the peptide sequence, and the predicted affinity.
Toxins 16 00271 g005
Figure 6. The newly identified evolutionary conserved stretch of 70 amino acids adopts a highly stable tertiary structure. Representation of native Zot protein encoded by genetic variant A0A1C7BT03 (A). Structural comparison of newly identified antigen between two of the least homologous P. aeruginosa strains (A0A1C7BT03 vs. O86426) show that they are analogous to each other by adopting the identical structural configuration (B). Sequence homology between Zot encoded A0A1C7BT03 and O86426 is estimated to be approximately 18% (C). Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged]. [conserved identical sequence (*); conserved mutation (:); semiconservative mutation (.)].
Figure 6. The newly identified evolutionary conserved stretch of 70 amino acids adopts a highly stable tertiary structure. Representation of native Zot protein encoded by genetic variant A0A1C7BT03 (A). Structural comparison of newly identified antigen between two of the least homologous P. aeruginosa strains (A0A1C7BT03 vs. O86426) show that they are analogous to each other by adopting the identical structural configuration (B). Sequence homology between Zot encoded A0A1C7BT03 and O86426 is estimated to be approximately 18% (C). Amino acid color alignments are based according to similarities in amino acid properties. [green, polar uncharged; magenta, positively charged; red, hydrophobic; blue, negatively charged]. [conserved identical sequence (*); conserved mutation (:); semiconservative mutation (.)].
Toxins 16 00271 g006
Table 1. A total of 126 protein entities and 38 species-specific bacteriophages were identified in UniProt and distributed among 8 different gram-negative bacterial (GNB) pathogens. Different UniProt accession numbers distributed according to species.
Table 1. A total of 126 protein entities and 38 species-specific bacteriophages were identified in UniProt and distributed among 8 different gram-negative bacterial (GNB) pathogens. Different UniProt accession numbers distributed according to species.
S. entericaP. aeruginosaA. baumanniiN. meningitidisV. choleraePhage
A0A379QXT6A0A0H2Z826A0A009IFH5A0A0A8FBH3ZOTA0A0D5YII2
A0A3J8T5J6A0A1B1XUY5A0A009IPH3A0A0G4BXF2A0A059TZ50A0A6H2UVW1
A0A3W0DS33A0A1C7BC45A0A0D5YHH3A0A0G4BXV5A0A0K1W029A0A6H3SDW9
A0A3Y5WWD0A0A1C7BT03A0A0J0ZVM8A0A0T7L458A0A0N9E639A0A7L5SKQ7
A0A5I0BDG5A0A1C7BWJ9A0A1S2G480A0A0U1RHW9A0A1X9T534A0A7Z7KXF7
A0A5I3CR81A0A1I1WSE1A0A241YA97A0A0U1RJQ1A0A2I7YRQ5A0A8B4N0A0
A0A5T2VLE5A0A241XLX8A0A2G1TM67A0A112F978A0A4D6FVS8G1P_BPF1
A0A5U8J4F5A0A367M4I3A0A432AJV1A0A425AZJ7A0A655SGS8G1P_BPFD
A0A5W2LVK4A0A3S0IVW1A0A5K1MT91A0A828RN06 G1P_BPI22
A0A5W2LW37A0A509J6G3A0A5N5XT91A0A828RNW2E. coliA0A1X3J1Y8
A0A5W8MDN4A0A509JD43A0A5P9QRB6A0A9N7GF23A0A4U9TGC6
A0A5X4GHS6A0A5E5R224A0A6F8TJW6A1KR73A0A2I5SNC4Q1RBR0
A0A5X8YFW4A0A643IWK8A0A6H2UVW1A9M0A6A0A3Y3VCH3A0A1D3HER3
A0A5Y0WW12A0A6B1YIK7A0A6H3EC82E0N6U2A0A3Y4Y4J3A0A378VUX0
A0A5Y2U2W8A0A6B1YIL4A0A6H3ECH2E3D282A0A444R958A0A6L2V467
A0A5Y2VPS7A0A6M3UYA0A0A6I4HQF2E3D468A0A8S7FTM0B4RJA3
A0A5Y6EM93A0A7L5EYC0A0A7U3Y721E6MVZ6A7ZLV6A0A0H5DLY7
A0A5Z4EMG4A0A7M2ZLS6A0A7U4DGM0E6N078 A0A0H5E090
A0A608IEZ3A0A7M2ZMC8A0A809JHA0Q9JRY6N. gonorrhoeaeA0A0Y6T6A1
A0A618GAJ0A0A844NQT0A0A829K5W9Q9JY47A0A112FLQ9
A0A619A930A0A894X9T7A0A829K9J2X5ENZ1D6H5P6A0A2X1UNH5
A0A619ACH0A0A9Q9JRM6A0A854NAT1 D6H5Q0VG301
A0A619ADY4B3G270A0A858S3M3 Q5F6B3VG424
A0A636GBL7B3G280A0A858S5Q5 Q5F6B6A0A6B9J7K7
A0A6X6T3T2B3G2P0A0A8B5UBY1 Q5F7K6A6VCB1
A0A715R1U3C6JW42A0A8I0FA89 Q56VN9
A0A720CYE7O86426A0A9Q2E630 K. pneumoniaeA0A0F6SIJ2
A0A729IWD7Q58CI5A0A9Q8M6J8 A0A0N9H972
A0A734CIM4Q9I5K2B0V4D4 A0A486UF20A0A650EUI2
A0A741P1A0 B0V4E4 A0A8H9ZV07A0A7D0JI66
A0A743NZG4 D0CAJ5 A0A9Q8EXA1A0A8E4CGG1
A0A743PB40 A0A9E8MB84
A0A743PEF2 Y. pestisF1CC69
A0A744EPC7 G8IRV1
A0A750EF42 A0A9P2VZ72Q64EV0
A0A750HM75 Q8W6D9
A0A750MS12 HumanQ0WEP2
A0A751YXV3
A0A757Y0U0 Q16625
A0A759HB29 Q07157
A0A759NSW2 Q9UDY2
A0A760RQA5 O95049
A0A974QHR0
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Benyamini, P. Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a “High Value” Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections. Toxins 2024, 16, 271. https://doi.org/10.3390/toxins16060271

AMA Style

Benyamini P. Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a “High Value” Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections. Toxins. 2024; 16(6):271. https://doi.org/10.3390/toxins16060271

Chicago/Turabian Style

Benyamini, Payam. 2024. "Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a “High Value” Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections" Toxins 16, no. 6: 271. https://doi.org/10.3390/toxins16060271

APA Style

Benyamini, P. (2024). Phylogenetic Tracing of Evolutionarily Conserved Zonula Occludens Toxin Reveals a “High Value” Vaccine Candidate Specific for Treating Multi-Strain Pseudomonas aeruginosa Infections. Toxins, 16(6), 271. https://doi.org/10.3390/toxins16060271

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop